Black Diamond Therapeutics to Present Preclinical and Clinic

04.10.2023 - CAMBRIDGE, Mass. and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) - Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing therapies that target families of oncogenic mutations in patients with ... Seite 1

Related Keywords

Helena Yu , Memorial Sloan Kettering Cancer Center , Preliminary Dose Escalation , Associate Attending Physician , Memorial Sloan Kettering Cancer , Preclinical Efficacy , Targeting Oncogenic , Upstream Driver , Elizabeth Buck , Chief Scientific Officer , Black Diamond , Poster Session ,